Cogent Biosciences (COGT) is back in focus after the FDA accepted its New Drug Application for bezuclastinib in NonAdvanced Systemic Mastocytosis, setting a December 30, 2026 action date with no review issues flagged.
See our latest analysis for Cogent Biosciences.
The FDA milestone and mixed institutional trading have come at a time when Cogent’s share price has been volatile, with a 1 day share price return of 6.08% and a 90 day share price return of 11.85%. The 1 year total shareholder return is very large and the 3 year total shareholder return is more than triple.
If this kind of biotech news has your attention, it could be a good moment to scan for other potential opportunities through our screener of 36 healthcare AI stocks
With Cogent shares up strongly over 1 year and trading at a large discount to the US$54.17 analyst price target, the key question now is simple: is there still a buying opportunity here, or has the market already priced in future growth?
Price to Book of 10.4x: Is It Justified?
Cogent Biosciences currently trades on a P/B of 10.4x, which puts the $35.41 share price at a very different level to many peers in the biotech space.
P/B compares the market value of the company to its net assets on the balance sheet, which can matter a lot for clinical stage biotechs that have limited revenue today. With Cogent still reporting a loss of $328.94m and less than $1m in revenue, investors are effectively paying for the pipeline, future cash flows and intellectual property rather than current earnings.
Relative to similar companies, Cogent screens as good value against its peer average P/B of 10.7x, yet looks expensive against the broader US Biotechs industry average of 2.5x. That contrast suggests the market is pricing Cogent closer to higher rated biotech names than to the wider group, while still not stretching beyond the tighter peer set.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 10.4x (ABOUT RIGHT)
However, there are clear risks here, including clinical or regulatory setbacks for bezuclastinib, along with ongoing large losses of US$328.94m and no meaningful revenue yet.
Find out about the key risks to this Cogent Biosciences narrative.
Next Steps
With sentiment clearly split between opportunity and risk, this is a moment to move quickly. Review the underlying data and reach your own conclusion using our 1 key reward and 3 important warning signs.
Looking for more investment ideas?
If you stop here, you only see part of the opportunity set. Use Simply Wall Street’s screeners to quickly surface stocks that match the kind of edge you want.
- Target potential mispricing by scanning 56 high quality undervalued stocks to find companies that combine quality fundamentals with prices the market has not fully recognised.
- Strengthen portfolio resilience by focusing on companies in the solid balance sheet and fundamentals stocks screener (39 results) that may be better positioned to handle financial stress.
- Spot early movers before the crowd by searching the screener containing 25 high quality undiscovered gems to identify businesses that quietly pair solid metrics with limited market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com